Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy
暂无分享,去创建一个
H. Iijima | H. Enomoto | S. Nishiguchi | N. Katakami | H. Nishikawa | Hironori Tanaka | Y. Iwata | N. Ishii | T. Nishimura
[1] Susan D Moffatt-Bruce,et al. Computed Tomography-Assessed Skeletal Muscle Mass as a Predictor of Outcomes in Lung Cancer Surgery. , 2019, The Annals of thoracic surgery.
[2] H. Muss,et al. Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review , 2019, Breast Cancer Research and Treatment.
[3] P. Philip,et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. , 2019, Cancer treatment reviews.
[4] T. Naito. Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia , 2019, Asia-Pacific journal of oncology nursing.
[5] K. Roberts,et al. Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[6] K. Pollard,et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice , 2019, Science.
[7] Y. Ogata,et al. Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer , 2019, AntiCancer Research.
[8] Y. Fujiwara,et al. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer. , 2019, Hepatobiliary & pancreatic diseases international : HBPD INT.
[9] Rong Liu,et al. Preoperative maximum standardized uptake value and carbohydrate antigen 19–9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma , 2019, BMC Cancer.
[10] Eugene J Koay,et al. Early Detection of Pancreatic Cancer: Opportunities and Challenges. , 2019, Gastroenterology.
[11] T. Fujiwara,et al. Clinical Impact of Sarcopenia on Gastric Cancer , 2019, AntiCancer Research.
[12] M. Beuran,et al. Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer. , 2019, Hepatobiliary & pancreatic diseases international : HBPD INT.
[13] W. Harmsen,et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. , 2019, Annals of surgery.
[14] G. Honda,et al. Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients , 2019, BMC Cancer.
[15] D. Jäger,et al. Chemotherapy for pancreatic cancer. , 2019, Presse medicale.
[16] P. Costelli,et al. The Skeletal Muscle as an Active Player Against Cancer Cachexia , 2019, Front. Physiol..
[17] A. Masamune,et al. Advances in Early Detection of Pancreatic Cancer , 2019, Diagnostics.
[18] C. Lu,et al. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model , 2019, Cancers.
[19] E. Gallardo,et al. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study , 2018, BMC Cancer.
[20] Wei Wang,et al. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC‐TNM staging , 2018, Surgery.
[21] R. Takata,et al. Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy. , 2017, Oncology letters.
[22] M. Reni,et al. A preoperative score to predict early death after pancreatic cancer resection. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[23] K. Shi,et al. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma , 2017, Journal of gastroenterology and hepatology.
[24] T. Ohtsuka,et al. Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis , 2017, Pancreas.
[25] T. Kanai,et al. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy , 2017, Cancer Chemotherapy and Pharmacology.
[26] S. Uemoto,et al. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. , 2016, Nutrition.
[27] W. Ichikawa,et al. Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX , 2016, Oncotarget.
[28] L. Wood,et al. Pancreatic cancer , 2016, The Lancet.
[29] T. Conroy,et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.
[30] J. Hodson,et al. A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[31] Masao Tanaka,et al. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. , 2016, European journal of cancer.
[32] Jarin Chindapasirt. Sarcopenia in Cancer Patients. , 2016, Asian Pacific journal of cancer prevention : APJCP.
[33] K. Hanada,et al. Diagnostic strategies for early pancreatic cancer , 2015, Journal of Gastroenterology.
[34] J. Furuse,et al. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. , 2014, Japanese journal of clinical oncology.
[35] Y. Inokawa,et al. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients , 2014, Surgery Today.
[36] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[37] H. Ueno,et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] K. Chayama,et al. Value of Cytodiagnosis Using Endoscopic Nasopancreatic Drainage for Early Diagnosis of Pancreatic Cancer: Establishing a New Method for the Early Detection of Pancreatic Carcinoma In Situ , 2012, Pancreas.
[39] M. Mcphail,et al. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. , 2012, Gastrointestinal endoscopy.
[40] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[41] Murray F. Brennan,et al. Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the Pancreas , 2004, Annals of surgery.
[42] N. Bardeesy,et al. Pancreatic adenocarcinoma. , 2014, The New England journal of medicine.
[43] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.